IV. Pharmacokinetic (PK) and anti-drug antibody (ADA) testing will be performed on all patients receiving MK-3475 (pembrolizumab). These analyses will evaluate: exposure-response analyses for activity and efficacy, potential pharmacodynamic biomarkers, and the safety of MK-3475 (pembrolizumab).